Deoxycorticosterone suppresses the effects of losartan in nitric oxide-deficient hypertensive rats

Journal of the American Society of Nephrology

Volumn 11, Issue 11, 2000, Pages 1995-2000

  De Gracia, Maria C ^a   Osuna, Antonio ^a   O'Valle, Francisco ^b   Del Moral, Raimundo G ^b   Wangensteen, Rosemary ^b   Del Rio, Cipriano Garcia ^b   Vargas, Felix ^b  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; DEOXYCORTICOSTERONE; LOSARTAN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY DISEASE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; GLOMERULOSCLEROSIS; HYPERTENSION; KIDNEY INJURY; MALE; MEAN ARTERIAL PRESSURE; MICROALBUMINURIA; NONHUMAN; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE;

EID: 0033760185     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Arnal JF, Warin L, Michel JB: Determinants of aortic cyclic guanosine monophosphate in hypertension induced by chronic inhibition of nitric oxide synthase. J Clin Invest 90: 647-652, 1992
2. Ribeiro MO, Antunes E, de Nucci G, Lovisolo SM, Zatz R: Chronic inhibition of nitric oxide synthesis: A new model of arterial hypertension. Hypertension 20: 298-303, 1992
3. Zatz R, Baylis C: Chronic nitric oxide inhibition model six years on. Hypertension 32: 958-964, 1998
4. Jover B, Herizi A, Ventre F, Dupont M, Mimran A: Sodium and angiotensin in hypertension induced by long-term nitric oxide blockade. Hypertension 21: 944-948, 1993
5. Pollock DM, Polakowski JS, Divish BJ, Opgenorth TJ: Angiotensin blockade reverses hypertension during long-term nitric oxide synthase inhibition. Hypertension 21: 660-666, 1993
6. Navarro-Cid J, Maeso R, Rodrigo E, Muñoz-García R, Riulope LM, Lahera V, Cachofeiro V: Renal and vascular consequences of the chronic nitric oxide synthase inhibition: Effects of antihypertensive drugs. Am J Hypertens 9: 1077-1083, 1996
7. Baylis C, Vallance P: Nitric oxide and blood pressure: Effects of nitric oxide deficiency. Curr Opin Nephrol Hypertens 5: 80-88, 1996
8. Selye H, Hall CE, Rowley EM: Malignant hypertension produced by treatment with desoxicorticosterone acetate and sodium chloride. Can Med Assoc J 49: 88-92, 1943
9. Hollenberg NK, Coletti C, Passan D: Hypertension, volume and vasoconstriction: studies on the renal blood supply in SHR, WKY and DOCA-salt rats models. Hypertens Res 15: 3-11, 1992
10. Naitoh M, Suzuki H, Arakawa K, Matsumoto A, Ichihara A Matsuda H, Kubota E, Murakami M, Nakamoto H, Saruta T: Role of kinin and renal ANG II blockade in acute effects of ACE inhibitors in low-renin hypertension. Am J Physiol 272: H679-H687, 1997
11. Kim S, Ohta K, Hamaguchi A, Omura T, Yukimura T, Miura K, Inada Y, Wada T, Ishimura Y, Chatani F, Iwao H: Role of angiotensin II in renal injury of deoxycorticosterone acetate-salt hypertensive rats. Hypertension 24: 195-204, 1994
12. Vargas F, Casanova I, Haro JM, Luna JD, García del Río C: The handling of NaCl load in rats during DOCA-salt and Goldblatt 2 kydney-1 clip hypertension development. Rev Esp Fisiol 44: 185-190, 1988
13. Alvarez G, Osuna A, Wangensteen R, Vargas F: Interaction between nitric oxide and mineralocorticoids in the long-term control of blood pressure. Hypertension 35: 752-757, 2000
14. Lacour C, Canals F, Galindo G, Cazaubon C, Segundy D, Nisato D: Efficacy of SR 47436 (BMS-186295), a non peptide angiotensin AT1 receptor antagonist in hypertensive rat models. Eur J Pharmacol 264: 307-316, 1994
15. Wada T, Kanagawa R, Ishimura Y, Inada Y, Nishikawa K: Role of angiotensin II in cerebrovascular and renal damage in deoxycorticosterone acetate-salt hypertensive rats. J Hypertens 13: 113-122, 1995
16. Chen K, Zhang X, Dunham EW, Zimmerman BG: Kinin-mediated antihypertensive effect of captopril in deoxycorticosterone acetate-salt hypertension. Hypertension 27: 85-89, 1996
17. Haber ET, Koemer LB, Page B, Kilman B, Purnode A: Application of radioimmunoassay for angiotensin I to the physiologic measurement of plasma renin activity in normal human subject. J Clin Endocrinol Metab 29: 1349-1355, 1969
18. Ferrario CM, Chappell MC, Tallant EA, Brosnihan KB, Diz DI: Counter-regulatory actions of angiotensin-(1-7). Hypertension 30: 535-541, 1997
19. 2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. Hypertension 31: 349-355, 1998
20. Navarro J, Sanchez A, Sálz J, Ruilope LM, García-Estañ J, Romero JC, Moncada S, Lahera V: Hormonal, renal and metabolic alterations during hypertension induced by chronic inhibition of NO in rats. Am J Physiol 267: R1516-R1521, 1994
21. Kim S, Himura M, Ikemoto F, Yamamoto K: Importance of glycosylation for hepatic clearance of renal renin. Am J Physiol 255: E642-E651, 1988
22. Kim S, Hosoi M, Himura M, Ikemoto F, Yamamoto K: Modification of glycosylation of renin in sodium-depleted and captopril treated rats. Am J Physiol 256: E798-E804, 1989
23. Arnal JF, el Amrani AI, Chatellier G, Ménard J, Michel JB: Cardiac weight in hypertension induced by nitric oxide synthase blockade. Hypertension 22: 380-387, 1993
24. Fernández-Rivas A, García-Estañ J, Vargas F: Effects of chronic increased salt intake on nitric oxide synthesis inhibition-induced hypertension. J Hypertens 13: 123-128, 1995
25. G-nitro-L-arginine methyl ester hypertension. Eur J Endocrinol 135: 506-513, 1996